Eliav Barr, Merck Research Laboratories chief medical officer
March 28, 2023 07:18 AM EDTUpdated 10:41 AM
R&D

Mer­ck touts PhI­II Keytru­da da­ta in front­line en­dome­tri­al can­cer

Katherine Lewin

News Reporter

In a boost to Mer­ck’s ef­forts of mov­ing block­buster drug Keytru­da to ear­li­er lines of treat­ment, Phase III da­ta in en­dome­tri­al can­cer pa­tients show sig­nif­i­cant …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Bio­phar­ma be­gins to con­tem­plate an RFK Jr.-in­flu­enced FDA if Trump wins

Pfiz­er shares new de­tails on obe­si­ty pipeline, hints at ‘oth­er op­por­tu­ni­ties’

GSK buys au­toim­mune T cell en­gager for $300M up­front from Chim­a­gen

No­var­tis takes $800M Mor­phoSys write­down mere months af­ter clos­ing ac­qui­si­tion

No­var­tis high­lights over­all M&A track record fol­low­ing Mor­phoSys im­pair­ment

Fol­low­ing March in­spec­tion, No­vo Nordisk's semaglu­tide man­u­fac­tur­ing fa­cil­i­ty cit­ed by FDA

A service from the Financial Times